SG11201708393UA - Sprinkle formulations of acamprosate - Google Patents
Sprinkle formulations of acamprosateInfo
- Publication number
- SG11201708393UA SG11201708393UA SG11201708393UA SG11201708393UA SG11201708393UA SG 11201708393U A SG11201708393U A SG 11201708393UA SG 11201708393U A SG11201708393U A SG 11201708393UA SG 11201708393U A SG11201708393U A SG 11201708393UA SG 11201708393U A SG11201708393U A SG 11201708393UA
- Authority
- SG
- Singapore
- Prior art keywords
- acamprosate
- sprinkle formulations
- sprinkle
- formulations
- Prior art date
Links
- AFCGFAGUEYAMAO-UHFFFAOYSA-N acamprosate Chemical compound CC(=O)NCCCS(O)(=O)=O AFCGFAGUEYAMAO-UHFFFAOYSA-N 0.000 title 1
- 229960004047 acamprosate Drugs 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/009—Sachets, pouches characterised by the material or function of the envelope
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562156842P | 2015-05-04 | 2015-05-04 | |
| US201562260161P | 2015-11-25 | 2015-11-25 | |
| PCT/US2016/030725 WO2016179252A1 (en) | 2015-05-04 | 2016-05-04 | Sprinkle formulations of acamprosate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201708393UA true SG11201708393UA (en) | 2017-11-29 |
Family
ID=57217823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201708393UA SG11201708393UA (en) | 2015-05-04 | 2016-05-04 | Sprinkle formulations of acamprosate |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10709668B2 (ja) |
| EP (1) | EP3291800A4 (ja) |
| JP (2) | JP7026347B2 (ja) |
| KR (1) | KR20170142180A (ja) |
| AU (1) | AU2016258624B2 (ja) |
| HK (1) | HK1252003A1 (ja) |
| IL (1) | IL255343B2 (ja) |
| SG (1) | SG11201708393UA (ja) |
| WO (1) | WO2016179252A1 (ja) |
| ZA (1) | ZA201708037B (ja) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016132136A1 (en) | 2015-02-18 | 2016-08-25 | Aston University | Diagnostic assay and treatment for preeclampsia |
| IL255343B2 (en) | 2015-05-04 | 2024-10-01 | Confluence Pharmaceuticals Llc | Essay formulations of acamprosate |
| AU2016303610A1 (en) * | 2015-08-04 | 2018-02-01 | Confluence Pharmaceuticals, Llc | Combination therapy using acamprosate and D-cycloserine |
| US12042566B2 (en) | 2017-05-17 | 2024-07-23 | Confluence Pharmaceuticals, Llc | Formulations of homotaurines and salts thereof |
| EP4213817A1 (en) * | 2020-09-21 | 2023-07-26 | Sun Pharmaceutical Industries Limited | Multi-particulate pharmaceutical composition of quetiapine |
| WO2023048065A1 (ja) | 2021-09-24 | 2023-03-30 | 住友ベークライト株式会社 | 脳波検出用電極、脳波測定装置及び脳波測定方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6514530B2 (en) | 1997-09-09 | 2003-02-04 | Alza Corporation | Dosage form comprising means for changing drug delivery shape |
| EP2338482A3 (en) | 1998-04-14 | 2011-12-21 | The General Hospital Corporation | Methods for treating neuropsychiatric disorders |
| RU2375048C2 (ru) * | 2003-07-17 | 2009-12-10 | Д-Р Редди'С Лабораторис Инк. | Фармацевтическая композиция с набухающим покрытием |
| DE102007009243A1 (de) | 2007-02-22 | 2008-09-18 | Evonik Röhm Gmbh | Pellets mit einer Wirkstoff-Matrix und einem Polymerüberzug, sowie ein Verfahren zur Herstellung der Pellets |
| US9308260B2 (en) | 2007-07-05 | 2016-04-12 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Anticonvulsive pharmaceutical compositions |
| EP2395990B1 (en) | 2009-02-12 | 2015-01-07 | Indiana University Research and Technology Corporation | Material and methods for treating developmental disorders including comorbid and idiopathic autism |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| US20110142889A1 (en) | 2009-12-16 | 2011-06-16 | Nod Pharmaceuticals, Inc. | Compositions and methods for oral drug delivery |
| CA2850468C (en) * | 2010-09-28 | 2019-08-13 | Depomed, Inc. | Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract |
| PL2727588T3 (pl) | 2011-03-01 | 2019-04-30 | Pharnext | Terapia zaburzeń neurologicznych oparta na baklofenie i akamprozacie |
| DK2688557T3 (da) * | 2011-03-23 | 2017-11-27 | Ironshore Pharmaceuticals & Dev Inc | Fremgangsmåder og sammensætninger til behandling af forstyrelse af opmærksomhed |
| JP5893135B2 (ja) | 2011-06-28 | 2016-03-23 | ビボゾーン インコーポレイテッド | 多重ターゲッティングの相乗効果を誘発する有効物質の組合せ及びその用途 |
| US20130143867A1 (en) | 2011-12-02 | 2013-06-06 | Sychroneuron Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
| JP2016520653A (ja) * | 2013-06-05 | 2016-07-14 | シンクロニューロン インコーポレイテッド | アカンプロサート製剤、それを用いる方法、およびそれを含む合剤 |
| CN106456583B (zh) | 2014-02-11 | 2020-04-07 | 法奈克斯公司 | 用于治疗神经障碍的巴氯芬、阿坎酸和中链甘油三酯的组合 |
| IL255343B2 (en) | 2015-05-04 | 2024-10-01 | Confluence Pharmaceuticals Llc | Essay formulations of acamprosate |
-
2016
- 2016-05-04 IL IL255343A patent/IL255343B2/en unknown
- 2016-05-04 SG SG11201708393UA patent/SG11201708393UA/en unknown
- 2016-05-04 AU AU2016258624A patent/AU2016258624B2/en active Active
- 2016-05-04 WO PCT/US2016/030725 patent/WO2016179252A1/en active Application Filing
- 2016-05-04 EP EP16789996.2A patent/EP3291800A4/en active Pending
- 2016-05-04 US US15/569,937 patent/US10709668B2/en active Active
- 2016-05-04 JP JP2017558372A patent/JP7026347B2/ja active Active
- 2016-05-04 KR KR1020177033137A patent/KR20170142180A/ko not_active Application Discontinuation
-
2017
- 2017-11-27 ZA ZA2017/08037A patent/ZA201708037B/en unknown
-
2018
- 2018-09-04 HK HK18111332.4A patent/HK1252003A1/zh unknown
-
2021
- 2021-06-22 JP JP2021103349A patent/JP2021155434A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20190046458A1 (en) | 2019-02-14 |
| ZA201708037B (en) | 2020-03-25 |
| HK1252003A1 (zh) | 2019-05-10 |
| JP2021155434A (ja) | 2021-10-07 |
| JP7026347B2 (ja) | 2022-02-28 |
| JP2018515506A (ja) | 2018-06-14 |
| AU2016258624A1 (en) | 2017-11-02 |
| IL255343B2 (en) | 2024-10-01 |
| EP3291800A1 (en) | 2018-03-14 |
| WO2016179252A1 (en) | 2016-11-10 |
| EP3291800A4 (en) | 2018-09-26 |
| IL255343B1 (en) | 2024-06-01 |
| IL255343A0 (en) | 2017-12-31 |
| AU2016258624B2 (en) | 2021-07-29 |
| KR20170142180A (ko) | 2017-12-27 |
| US10709668B2 (en) | 2020-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT3523390T (pt) | Utilização de composições à base de tetrafluoropropeno | |
| EP3270960A4 (en) | Vector formulations | |
| HK1251149A1 (zh) | L-鳥氨酸苯乙酸鹽製劑 | |
| HK1252003A1 (zh) | 阿坎酸散劑 | |
| IL265856A (en) | Preparations for the administration of aflornithine | |
| HK1252053A1 (zh) | 新型閉塞製劑 | |
| EP3223607C0 (en) | EDIBLE MORPHOLINE-FREE COATING FORMULATIONS | |
| GB201522764D0 (en) | Formulations of phosphate derivatives | |
| PL3943070T3 (pl) | Preparaty bedakiliny o długotrwałym działaniu | |
| IL272857A (en) | Cofanalisib formulations | |
| EP3265177C0 (en) | FORMULATIONS OF HYDROPHILIC COMPOUNDS | |
| IL267279A (en) | Pharmaceutical formulations of suvorexant | |
| ZA201803032B (en) | Pharmaceutical compositions of dimethyl fumarate | |
| PT3678644T (pt) | Formulações de copanlisib | |
| IL258420A (en) | Stable formulations of fingolimod | |
| GB201805338D0 (en) | Cosmetic formulations | |
| HUE057047T2 (hu) | Turmeronokat tartalmazó bõrkezelõ készítmények | |
| GB201621867D0 (en) | Novel formulations of aprepitant | |
| GB201621277D0 (en) | Formulations | |
| AU2016904621A0 (en) | Improved uses of new formulations | |
| GB201618110D0 (en) | Formulations | |
| GB201616366D0 (en) | Formulations | |
| GB201615754D0 (en) | Formulations | |
| AU2016904267A0 (en) | Uses of new formulations | |
| GB201609903D0 (en) | Therapeutic compositions |